Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
03/23/2017 03/24/2017 03/27/2017 03/28/2017 03/29/2017 Date
54(c) 54.33(c) 52.6(c) 54.47(c) 54.2(c) Last
152 514 182 546 158 074 174 675 172 069 Volume
+1.89% +0.61% -3.18% +3.56% -0.50% Change
More quotes
Financials (€)
Sales 2017 52,3 M
EBIT 2017 -43,4 M
Net income 2017 -46,4 M
Finance 2017 257 M
Yield 2017 -
Sales 2018 46,4 M
EBIT 2018 -40,2 M
Net income 2018 -53,1 M
Finance 2018 178 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 25,3x
EV / Sales2018 30,3x
Capitalization 1 580 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
03/29 DGAP-DD : MorphoSys AG english
03/29 DGAP-DD : MorphoSys AG deutsch
03/23 MORPHOSYS AG : MorphoSys's CSO Marlies Sproll Takes Temporary Leave, Markus Enze..
03/23 MORPHOSYS : CSO Marlies Sproll Takes Temporary Leave Markus Enzelberger to Serve..
03/23 DGAP-NEWS : MorphoSys' Forschungsvorstand Marlies Sproll nimmt vorübergehend Aus..
03/23 DGAP-NEWS : MorphoSys's CSO Marlies Sproll Takes Temporary Leave Markus Enzelber..
03/09 MORPHOSYS : Patent Issued for Combinations and Uses (USPTO 9579378)
03/09 MORPHOSYS AG : Presents Strong Results for Fiscal Year 2016
03/09 MORPHOSYS : Presents Strong Results for Fiscal Year 2016
03/09 DGAP-NEWS : MorphoSys AG berichtet über ein starkes Geschäftsjahr 2016
More news
Sector news : Biotechnology & Medical Research - NEC
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
03/23MorphoSys AG's CSO Takes Temporary Leave  
03/23MorphoSys AG : MorphoSys's CSO Marlies Sproll Takes Temporary Leave, Markus E.. 
03/09MorphoSys AG reports Q4 results  
03/09MorphoSys AG 2016 Q4 - Results - Earnings Call Slides  
03/09MorphoSys buy #Finanzierung  
More tweets
Qtime:12
News from SeekingAlpha
03/09 MorphoSys' (MPSYF) CEO Simon Moroney on Q4 2016 Results - Earnings Call Trans..
03/09 MorphoSys AG reports Q4 results
03/09 MorphoSys AG 2016 Q4 - Results - Earnings Call Slides
01/12 Novartis to launch mid-stage study of bimagrumab in obese type 2 diabetics
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
Advertisement
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 66,5 €
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Marlies Sproll Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG11.18%1 700
INCYTE CORPORATION38.91%28 388
QUINTILES IMS HOLDINGS..3.48%18 909
LONZA GROUP AG3.18%10 797
CELLTRION, INC.--.--%9 883
ALKERMES PLC7.50%9 115
More Results